Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Net Cash Flow: 2013-2025

Historic Net Cash Flow for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to -$46.4 million.

  • Ocular Therapeutix's Net Cash Flow fell 42.78% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.4 million, marking a year-over-year decrease of 126.05%. This contributed to the annual value of $196.1 million for FY2024, which is 109.77% up from last year.
  • As of Q3 2025, Ocular Therapeutix's Net Cash Flow stood at -$46.4 million, which was down 211.84% from $41.5 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Net Cash Flow registered a high of $287.1 million during Q1 2024, and its lowest value of -$46.4 million during Q3 2025.
  • Its 3-year average for Net Cash Flow is $22.0 million, with a median of -$23.3 million in 2023.
  • In the last 5 years, Ocular Therapeutix's Net Cash Flow tumbled by 197.20% in 2021 and then skyrocketed by 1,333.48% in 2024.
  • Ocular Therapeutix's Net Cash Flow (Quarterly) stood at -$15.1 million in 2021, then fell by 23.37% to -$18.6 million in 2022, then skyrocketed by 557.14% to $85.3 million in 2023, then slumped by 141.19% to -$35.1 million in 2024, then plummeted by 42.78% to -$46.4 million in 2025.
  • Its Net Cash Flow was -$46.4 million in Q3 2025, compared to $41.5 million in Q2 2025 and -$42.4 million in Q1 2025.